Takeda Ends $260M Wave Partnership for Huntington’s Disease, Wave Pursues New Paths

Takeda has decided to withdraw from its collaboration with Wave Life Sciences, ending its involvement with the WVE-003 program for Huntington’s disease after a significant investment of $260 million since 2018[1][2]. Initially part of a substantial agreement that included a $110 million deal, $60 million equity, and additional research funding, Takeda decided to opt out following the review of promising Phase Ib/IIa data that demonstrated reduced mutant huntingtin levels[2]. Despite this termination, Wave remains optimistic, secure in their financial standing and the $5 billion commercial potential of the WVE-003 program[1][2].